Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice
Completed
- Conditions
- Asthma
- Registration Number
- NCT00782314
- Lead Sponsor
- AstraZeneca
- Brief Summary
We want to evaluate efficacy of Symbicort® Turbuhaler® (formoterol/budesonide) therapy for asthma in real life conditions. For this purpose we will include both patients that are treated with Symbicort® Turbuhaler® the "classical" maintenance only treatment approach as well as those treated with the SMART approach.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
- patients diagnosed with persistent asthma treated with Symbicort® Turbuhaler® in line with its label
- non-pregnant females
- existing maintenance only treatment with Symbicort® Turbuhaler® 80 μg/4,5 μg, 160 μg/4,5 μg or 320 μg/9 μg for at least 1 month
- existing SMART treatment with Symbicort® Turbuhaler® 80 μg/4,5 μg or 160 μg /4,5 μg for at least 1 month
Exclusion Criteria
- patients not being treated with Symbicort® Turbuhaler®
- patients treated with Symbicort® Turbuhaler® for COPD
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method to determine the efficacy of both possible treatment approaches with Symbicort® Turbuhaler®, measured by asthma control three times: 0, 3, 6 months after inclusion
- Secondary Outcome Measures
Name Time Method to determine the number of maintenance and reliever inhalations of Symbicort® Turbuhaler®, as well as the concomitant usage of a separate reliever inhaler even in the case of SMART treatment approach three times: 0, 3, 6 months after inclusion
Trial Locations
- Locations (1)
Research Site
🇸🇮Zagorje, Slovenia